All In Biotech

Drug Trial Radar · NCT07942766

A Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)

A Phase IIa, Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of HW201877 Capsule in the Treatment of Moderate to Severe Active Inflammatory Bowel Disease (IBD)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIa, open-label, multicenter clinical trial that plans to enroll approximately 20 patients each with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) who have had an inadequate response, loss of response, or intolerance to prior therapies. Participants will receive 12 weeks of the investigational study drug to provide a preliminary assessment of its efficacy and safety.

Conditions

  • Inflammatory Bowel Disease (IBD)

Interventions

  • HW201877 capsulesDrug

    HW201877 oral capsule,12W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 • Proportion of participants achieving clinical remission based on the modified Mayo score at Week 12;Time frame: At week 12
  2. Cohort 2 Co-primary endpoints: • Proportion of participants achieving symptomatic remission at Week 12;Time frame: At week 12
  3. Cohort 2 Co-primary endpoints: • Proportion of participants achieving endoscopic response at Week 12.Time frame: At week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renmin hospital of Wuhan University

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.